信立泰(002294.SZ)：SAL0140获得临床试验批准通知书

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration to conduct clinical trials for its innovative small molecule drug SAL0140, aimed at treating primary aldosteronism [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company [1] - The drug is intended to target conditions such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1] - Aldosterone plays a crucial role in maintaining fluid and electrolyte balance and is involved in various cardiovascular and renal diseases [1] Group 2: Market Potential - Aldosterone synthase inhibitors are expected to lower aldosterone levels in patients with primary aldosteronism, potentially reducing blood pressure and organ damage [1] - The development of SAL0140 presents significant potential in the market due to its targeted therapeutic applications [1]